(S (S (NP (NP (JJ Uncompetitive) (NNS antagonists)) (PP (IN of) (NP (NP (DT the) (NNP N-methyl) (NNP D-aspartate) (NN receptor)) (PRN (-LRB- -LRB-) (NP (NNP NMDAR)) (-RRB- -RRB-))))) (VP (VBP have) (VP (VBN demonstrated) (NP (JJ therapeutic) (NN benefit)) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (JJ neurological) (NNS diseases)) (PP (JJ such) (IN as) (NP (NP (NNP Parkinson) (POS 's)) (CC and) (NP (NNP Alzheimer) (POS 's))))))))))) (, ,) (CC but) (S (NP (DT some)) (ADVP (RB also)) (VP (VBP cause) (NP (NP (JJ dissociative) (NNS effects)) (SBAR (WHNP (WDT that)) (S (VP (VBP have) (VP (VBN led) (PP (TO to) (NP (NP (DT the) (NN synthesis)) (PP (IN of) (NP (NN illicit) (NNS drugs)))))))))))) (. .))
(S (NP (DT The) (NN ability) (S (VP (TO to) (VP (VB generate) (NP (NNP NMDAR) (NNS antagonists)) (PP (IN in) (NP (NN silico))))))) (VP (VBZ is) (ADVP (RB therefore)) (ADJP (JJ desirable) (PP (DT both) (PP (IN for) (NP (JJ new) (NN medication) (NN development))) (CC and) (PP (IN for) (S (VP (VBG preempting) (CC and) (VBG identifying) (NP (JJ new) (NN designer) (NNS drugs)))))))) (. .))
(S (ADVP (RB Recently)) (, ,) (NP (JJ generative) (NN deep) (NN learning) (NNS models)) (VP (VBP have) (VP (VBN been) (VP (VBN applied) (PP (TO to) (NP (ADJP (VB de) (JJ novo)) (NN drug) (NN design))) (PP (IN as) (NP (NP (DT a) (NN means)) (SBAR (S (VP (TO to) (VP (VB expand) (NP (NP (DT the) (NN amount)) (PP (IN of) (NP (NN chemical) (NN space))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB be) (VP (VBN explored) (PP (IN for) (NP (JJ potential) (JJ drug-like) (NNS compounds)))))))))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN study))) (, ,) (NP (PRP we)) (VP (VBP assess) (NP (NP (DT the) (NN application)) (PP (IN of) (NP (DT a) (JJ generative) (NN model))) (PP (TO to) (NP (DT the) (NNP NMDAR))) (S (VP (TO to) (VP (VB achieve) (NP (NP (CD two) (JJ primary) (NNS objectives)) (: :) (NP (NP (PRN (-LRB- -LRB-) (NN i) (-RRB- -RRB-)) (NP (NP (DT the) (NN creation) (CC and) (NN release)) (PP (IN of) (NP (NP (DT a) (JJ comprehensive) (NN library)) (PP (IN of) (NP (NP (ADJP (RB experimentally) (VBN validated)) (NNP NMDAR) (NN phencyclidine) (PRN (-LRB- -LRB-) (NNP PCP) (-RRB- -RRB-)) (NN site) (NNS antagonists)) (SBAR (S (VP (TO to) (VP (VB assist) (NP (DT the) (NN drug) (NN discovery) (NN community)))))))))))) (CC and) (NP (PRN (-LRB- -LRB-) (NN ii) (-RRB- -RRB-)) (NP (NP (DT an) (NN analysis)) (PP (IN of) (NP (CC both) (NP (NP (DT the) (NNS advantages)) (VP (VBN conferred) (PP (IN by) (S (VP (VBG applying) (NP (JJ such) (JJ generative) (JJ artificial) (NN intelligence) (NNS models)) (PP (TO to) (NP (NN drug) (NN design)))))))) (CC and) (NP (NP (DT the) (JJ current) (NNS limitations)) (PP (IN of) (NP (DT the) (NN approach))))))))))))))) (. .))
(S (NP (PRP We)) (VP (VP (VBP apply)) (, ,) (CC and) (VP (VB provide) (NP (NP (NN source) (NN code)) (PP (IN for)))) (, ,) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NP (ADJP (JJ ligand-) (CC and) (JJ structure-based)) (NN assessment) (NNS techniques)) (VP (VBN used) (PP (IN in) (NP (JJ standard) (NN drug) (NN discovery) (VBZ analyses))))))) (PP (TO to) (NP (DT the) (JJ deep) (JJ learning-generated) (NNS compounds)))) (. .))
(S (NP (PRP We)) (VP (VBP present) (NP (NP (JJ twelve) (NN candidate) (NNS antagonists)) (SBAR (WHNP (WDT that)) (S (VP (VBP are) (RB not) (JJ available) (PP (IN in) (NP (VBG existing) (NN chemical) (NNS databases))))))) (S (VP (TO to) (VP (VB provide) (NP (NP (DT an) (NN example)) (PP (IN of) (SBAR (WHNP (WP what)) (S (NP (NP (DT this) (NN type)) (PP (IN of) (NP (NN workflow)))) (VP (MD can) (VP (VB achieve)))))))))) (, ,) (SBAR (IN though) (S (NP (NP (NP (NN synthesis)) (CC and) (NP (JJ experimental) (NN validation))) (PP (IN of) (NP (DT these) (NNS compounds)))) (VP (VBZ is) (ADVP (RB still)) (VP (VBN required)))))) (. .))
